Angela Celestin, executive vice president and chief human resources officer for CareFirst BlueCross BlueShield, had a career outside of healthcare before working at CareFirst. “Healthcare was going through some major changes, and I wanted to be part of that change,” she says.
The FDA’s accelerated pathway gets drugs to market quickly, but it also can mean patients are put on therapies that do not actually provide a clinical benefit.
Vaxneuvance is approved for 15 serotypes, including those that are major causes of disease.
Some see the upward trend in cancer drug costs as accelerating — and unsustainable. Value-based pathways might rearrange the incentives to put some downward pressure on prices.
An advisory committee recommends against approving an anemia drug. Darzalex Faspro receives another indication, Bayer receives approval for Kerendia for chronic kidney disease, and FDA delays its decision on sNDAs for JAK inhibitor therapies for atopic dermatitis.
Koleen Cavanaugh, vice president of marketing at Independence Blue Cross in Philadelphia, says starting in customer service was the best thing for her career.
In this week's episode, Associate Editor, Briana Contreras spoke with Dr. Florian Otto, co-founder and CEO for Cedar, a complete healthcare financial engagement platform. Dr. Otto discussed the topic of compassionate billing and how this particular payment model is becoming triumphant over traditional healthcare payment models where patients are experiencing an increase in insurance deductibles and out-of-pocket medical expenses.
The first generic of the high-dose intravenous iron, a generic of Feraheme, is now available.
Researchers are documenting how income volatility is affecting the middle class and healthcare decisions of its members.
Biogen officials defended the company's Alzheimer's drug and criticized ICER's cost-effectiveness report today at a meeting of one of the group's advisory committees. But the committee cast a series of votes that showed the members have a low opinion of the drug.
Committee members raised safety concerns about FibroGen/AstraZeneca’s oral therapy roxadustat.
Several large payers are waiting on results from the National Coverage Determination.
After generic entry, Zytiga’s market share fell to about 14% and monthly net sales across the entire market fell 85%.
With the COVID-19 pandemic almost in our rear-view mirror, we stand on the horizon of a profound change in healthcare: The evolution of primary care from a static provider relationship to a virtual care team in your pocket.
Romilla Batra, M.D., MBA, chief medical officer of SCAN Health and a professor of medicine at University of California, Irvine, says she was drawn to working for SCAN because “its mission resonated so strongly with me."
New analysis suggests that even with rebates, the new Alzheimer’s therapy could have implications for Medicaid drug spending.
International Generic and Biosimilar Medicines Association recently released the report, "A Vision for the Global Generic and Biosimilar Medicines Industry,” covering the current global Generic and Biosimilar medicine industry, and released a vision of what the market will be in 2030 and how to achieve it.
ICER has entered the fray and is holding virtual public meeting tomorrow.
The first generic equivalent of the HIV therapeutic is now available.
Research note from SVB Leerink says revenue erosion once biosimilars hit the market in 2023 may be more gradual than some prior predictions.
The therapy for opioid-induced constipation has no restrictions on an unidentified national formulary that serves these Blues plans.
The new indication provides a subcutaneous option for multiple myeloma that can be administrated in minutes, rather than hours.
Home-based testing could be a less expensive way to improve preventive care.
The review will determine whether there should be a national Medicare coverage policy for the Alzheimer’s therapy.
Low prices and some gaming of regulations can drive out competitors and create monopolies that allow generic makers to jack up their prices. Experience has shown that it often takes multiple generics to achieve the promised-for downward pressure on prices.
Harvard clinicians say the case for mandating COVID-19 vaccination is stronger than it is for mandating flu shots — and give eight reasons why
Burnout is a long-standing issue among staff in healthcare and a key contributor to America’s on-going nurse shortage, says Karlene Kerfoot in this opinion piece.
Commercial insurers are beginning to provide coverage information on Biogen’s controversial therapy.
To say that Covid-19 has permanently transformed the meetings and events landscape would be stating the obvious, authors share in this opinion piece.
Findings from industry studies show major cost savings for beneficiaries in Medicare Advantage plans. Some say the cost per enrollee for the government is higher than that for traditional Medicare.
